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ABSTRACT
Purpose: Neuroendocrine carcinomas (NEC) of the prostate are rare, with only a few series hitherto reported. The ob-
jective of this study was to assess in a single institution the clinical and morphologic characteristics of neuroendocrine 
carcinomas diagnosed in needle core biopsies.
Materials and Methods: The current study analyses seven cases diagnosed in needle biopsies at a large tertiary regional 
cancer center from Northeastern Brazil. Two pathologists reviewed specimens retrospectively, and demographic and 
morphologic characteristics were compared to 458 acinar tumors diagnosed in the same period.
Results: There were five small cell carcinomas and two low-grade neuroendocrine carcinomas (carcinoid). NEC were 
associated with an acinar component in 5/7  cases and the Gleason score of the acinar component was always > 6. The 
number of cores involved in prostates with NEC was greater (65% compared to 24% of acinar tumors, p < 0.05). The 
mean PSA at diagnosis was 417.7 (range 5.7-1593, SD 218.3), compared to 100.5 (p = 0.1) of acinar tumors (range 0.3-
8545, SD 22.7). Prostates harboring NEC were bigger (p < 0.001, mean volume 240 mL vs. 53 mL of acinar tumors). 
Treatment of NEC included palliative surgery, chemotherapy, and hormonal therapy.
Conclusions: NEC of the prostate is rare and often associated with a high-grade acinar component. Prostates with NEC 
tend to be larger and involve a greater number of cores than acinar tumors. PSA at diagnosis does not seem to predict the 
presence of NE tumors in needle biopsy.
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Neuroendocrine carcinomas (NEC) of the 
prostate are rare, representing less than 0.5% of pros-
tate carcinomas in the few series reported to date (1-8). 
The current classification of neuroendocrine carcino-
mas is based on the World Health Organization 2004 
lung tumor classification, and it divides those tumors 
into well-differentiated neuroendocrine carcinomas 
(carcinoid tumors), moderately-differentiated neu-
roendocrine carcinomas (atypical carcinoid tumors), 
and poorly-differentiated neuroendocrine carcino-
mas, which include two morphologic distinct entities 
(small cell carcinomas and large cell neuroendocrine 
carcinomas) (9). The classification is based solely on 
histomorphology and relies on both light microscopy 
and immunohistochemical studies.
 Albeit rare, the most common neuroendo-
crine carcinoma of the prostate is by far small cell car-
cinoma. Furthermore, it is estimated that up to 10% 
of prostate cancer in patients with androgen-resistant 
disease after long-term androgen deprivation therapy 
are high grade NEC, most with associated acinar ad-
enocarcinoma (10).
 Recognition of this entity via needle biopsies 
is critical, as its therapy differs significantly from that 
of usual acinar high-grade prostatic adenocarcinoma.
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MATERIALS AND METHODS
Seven cases of neuroendocrine carcinomas 
primary to the prostate were collected over 4 years 
(2006-2010) from the Department of Pathology ar-
chives of the Cancer Hospital of the Ceara Cancer 
Institute among 465 sequential needle biopsies from 
the in-house Urology Department Service. Patients 
with neuroendocrine tumors primary to other sites 
were excluded from the study.
The morphologic data independently collect-
ed and reviewed by two pathologists (FT and CDM) 
were basic morphology to include small or non-small 
cell pattern, percentage of cores involved, associa-
tion with conventional acinar adenocarcinoma and 
the Gleason grading, mitotic rate, presence of tumor 
necrosis and any other morphologic findings.
Immunohistochemical studies were per-
formed on the available paraffin blocks in all seven 
cases. Immunohistochemistry was performed in our 
laboratory using the standard streptavidin-biotin-
peroxidase procedure. Primary monoclonal antibod-
ies to PSA (dilution 1:100), chromogranin (1:2000), 
synaptophysin (1:50), ki67 (1:100) and p63 (1:300) 
(Dako Inc., Carpinteria, USA) were applied to 5-mm 
thick 10% formalin-fixed, paraffin-embedded tissue 
sections. The sections underwent a process of de-
paraffinization, rehydration, and washing in xylene, 
graded alcohols, and distilled water. Blockage of en-
dogenous peroxide activity was performed by incu-
bation with 3% H2O2. The sections were placed in 10 
mM citrate buffer at pH 6 with subsequent antigen re-
trieval procedure. The antigen-antibody reaction was 
visualized using the avidin-biotin peroxidase com-
plex and diaminobenzidine as the chromogen. Slides 
were counterstained with hematoxylin. Positive re-
sults consisted of dark brown nuclear (p63, ki67) and 
cytoplasmic (chromogranin, synaptophysin) staining 
and cytoplasmic and luminal granular staining of se-
cretory epithelial cells by PSA. Appropriate positive 
and negative controls were included. Only staining 
that was moderate or strong was considered positive.
 Clinical follow-up was possible in all but 
one case by retrospective clinical chart review by 
one of the authors (MVL).
 Clinical and histopathologic variables were 
compared among categorized groups using the χ2 
test or Student t- test. A p value less than 0.05 was 
considered significant. The software SPSS 5.0 (Chi-
cago, IL) was used for statistical analyses.
RESULTS
 The clinical and pathological characteristics 
of the seven cases are summarized in Tables 1 and 2. 
Those cases were retrieved spanning four years and 
included all needle biopsies performed at the Urolo-
gy Department at our institution among 465 sequen-
tial biopsies (1.5%). The mean age at diagnosis was 
69.8 years. Metastatic NEC from any other site or 
direct extension from the bladder or gastrointestinal 
tract were excluded clinically in all cases. The se-
rum PSA values at the time of initial diagnosis were 
available in 5 patients and ranged from 7.3 to 1449.0 
ng/mL (mean 461.1 ng/mL, median 194.15 ng/mL).
 There were five small cell carcinomas and 
two tumors with morphology and mitotic count 
compatible with low-grade neuroendocrine carci-
nomas (carcinoid). There was no significant dif-
ference in tumor extent in biopsies between small 
cell carcinomas and carcinoid tumors. The numbers 
of cores obtained in the needle biopsies diagnosed 
with prostatic neuroendocrine tumors were six in 
two cases, eight cores in four cases and 12 cores 
in one case. NEC were associated with an acinar 
component in five of seven cases and the Gleason 
score of the acinar component was always > 6 (Fig-
ures 1-3). One patient had a Gleason score of 3+4, 
a second 4+4, and a third 5+4 (Table-1). The five 
tumors with associated acinar adenocarcinomas in 
the biopsies involved a higher number of cores than 
the two tumors without an acinar component, but the 
difference was not significant. NEC tended to frag-
ment in needle cores, and histologic crush artifact 
was also a common feature (Figure-4). Tumor ne-
crosis was common and present at least focally in 
six of seven cases (Figure-5). Cytologically, tumor 
cells were small, with scant cytoplasm and open 
chromatin, with inconspicuous nucleoli (Figure-6). 
Immunohistochemical findings included positiv-
ity for neuroendocrine epitopes (chromogranin and 
synaptophysin) in all tumors with varying degrees of 
positivity. Chromogranin was stronger overall. The 
Ki-67 proliferative index varied from 40 to 90% in 
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Figure 1 - Low power of small cell carcinoma (left) associated 
with Gleason 8 acinar adenocarcinoma (right). Hematoxilin-
eosin, 40x. 
Figure 2 - Small cell carcinoma associated with acinar 
adenocarcinoma. On the upper right corner, small cell 
carcinoma predominates, whereas acinar Gleason pattern 3 can 
be seen in the left lower corner. Hematoxilin-eosin, 200x.
Figure 3 - Small cell carcinoma in close association with 
Gleason 4+3 acinar adenocarcinoma (same case as Figure-4). 
Hematoxilin-eosin, 100x.
Figure 4 - Medium-power view of small cell carcinoma. The 
tumor tends to fragment on processing. Hematoxilin-eosin, 100x.
Figure 5 - Small cell carcinoma. Punctuate tumor necrosis is a 
common finding. Also note the desmoplastic stroma surrounding 
tumor nests. Hematoxilin-eosin, 200x.
Figure 6 - Small cell cacinoma, cytologic findings. Small 
cell carcinoma. Nucleoli are inconspicuous and cytoplasm 
are scant. Hematoxilin-eosin, 200x.
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five available cases. PSA immunohistochemistry 
was only weakly positive in NEC in 2 cases (Fig-
ures 7-10).
 During the same period, data on 458 con-
ventional type acinar adenocarcinomas were re-
viewed and compared with the seven cases on this 
study. Of the 458 cases, there were 191 Gleason 6, 
131 Gleason 7, 72 Gleason 8, 33 Gleason 9 and 7 
Gleason 10. The mean age at diagnosis correspon-
dent to Gleason 6-10 were 69.1, 70.3, 74.2, 73.6 
and 76.2 (p < 0.001). Within the acinar tumors, 
high grade tumors (Gleason > 7) also correlated 
with a high PSA at diagnosis (p < 0.001), but not 
with prostate volume (p = 0.3). The ratio of PSA/
volume significantly correlated with a high Glea-
son score (p < 0.05).
 The number of cores involved in prostates 
with NEC was greater (65% compared to 24% of 
acinar tumors, p < 0.05). The mean PSA at diag-
nosis was 417.7 (range 5.7-1593, SD 218.3), com-
pared to 100.5 (p = 0.1) of acinar tumors (range 
0.3-8545, SD 22.7). Prostates harboring NEC were 
bigger (p < 0.001, mean volume 240 mL vs 53 mL 
of acinar tumors).
 Follow-up was available in six patients. 
Treatment of our patients included chemotherapy 
and hormonal therapy, as well as palliative sur-
gery. Most patients were diagnosed in an advanced 
Figure 7 - High grade neuroendocrine carcinoma with strong 
positivity for chromogranin immunostain.
Figure 8 - PSA immunostain showing strong positivity in benign 
prostate glands, whereas the neuroendocrine tumor is faint to 
absent.
Figure 9 - Occasional neuroendocrine carcinoma tumor cells 
were positive for PSA immunostain.
Figure 10 - Ki-67 showed a high proliferative index in most 
neuroendocrine tumors.
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stage, precluding the possibility of radical prosta-
tectomy. Three patients underwent palliative sur-
gery: one was treated with transurethral resection 
only for obstruction, a second with transurethral 
resection followed by surgical castration (orchiec-
tomy) and a third with colostomy for intestinal ob-
struction by metastatic tumor. Three patients were 
treated with chemotherapy in association with eto-
poside phosphate (VP-16) and cisplatin (CDDP). 
In one of these patients, chemotherapy was sus-
pended after one cycle due to obstructive renal 
failure, whereas in another patient the regimen was 
modified to taxol after the fourth cycle, but with 
no measurable response. Mean follow-up was 13.7 
months, with a range of 2.1 months in two patients 
with distant metastatic disease at diagnosis (bone 
in one, and bone and liver in the second), to 26.6 
months in a patients who is alive with disease at 
last follow-up (Table-2).
DISCUSSION
 The morphologic features of NEC of the 
prostate are similar to those of other sites, including 
the common pulmonary small cell carcinomas (9). In 
prostate neuroendocrine carcinoma series, however, 
a common finding is the association with conven-
tional acinar tumors, suggesting a common pathway 
of tumor differentiation, or a neuroendocrine trans-
formation from the better-differentiated carcinoma 
to neuroendocrine tumor (7,11). In the current study, 
only of the cases showed associated conventional 
type cancer; however, it is noteworthy that these 
were all diagnosed on needle biopsies, and one can 
not exclude another tumor components if the tumors 
were resected and examined throughout.
 The diagnosis of high-grade neuroendo-
crine carcinomas in a needle biopsy may be chal-
lenging to the pathologists, especially because of 
the important clinical implication, which is exclu-
sion from tentative surgical treatment with curative 
intent. None of the patients in the series were taken 
to radical prostatectomy, with two patients under-
going transurethral resection for obstructive dis-
ease palliative management. This data underscores 
the need for new therapeutic strategies to treat these 
tumors, which may include the use of protocols that 
have been effective against neuroendocrine carci-
nomas arising in other organ systems (6,12-14).
 In cases where the diagnosis of small cell 
carcinoma is difficult, either due to the limited ma-
terials available, or due to lack of clear neuroen-
docrine differentiation, where the main differential 
is always with high-grade Gleason 9 or 10 acinar 
prostate adenocarcinomas, and poorly differenti-
ated urothelial tumors invading the prostate, immu-
nohistochemistry can be helpful. The vast majority 
of these tumors express at least one neuroendo-
crine marker. Wang et al. reported a rate of 94%, 
being CD56 the most sensitive (7).  One caveat is 
that conventional adenocarcinomas, up to 100% 
in some studies, may focally express these same 
markers, reinforcing the need for careful morpho-
logic evaluation by the pathologist (5,15,16). More 
recent discoveries have suggested that prostatic 
specific membrane antigen (PSMA), CD44 and 
protein (P501S) may help with indentifying neuro-
endocrine expression in tumors (7,17).
 High-grade neuroendocrine carcinomas 
have been reported in association with obstructive 
symptoms in the setting of androgen-independent 
disease. In this scenario, serum PSA levels tend to 
be low to undetectable. In the current series, all 
cases were diagnosed de novo with a high mean 
PSA, indicating that those tumors or the associated 
acinar tumor are able to express high quantities of 
PSA. Interestingly, we have found no association 
of serum PSA levels and PSA detection on the tis-
sue by immunohistochemistry (Tables 1 and 2).
CONCLUSIONS
 Prostates harboring neuroendocrine carci-
noma tend to be larger and involve a greater num-
ber of cores than acinar tumors. Association with 
conventional acinar tumors is common. Serum 
PSA levels vary greatly and its value at diagnosis 
does not seem to predict the presence of NE tumors 
in needle biopsy.
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